

43rd PLENARY MEETING OF THE SCIENTIFIC PANEL ON DIETETIC PRODUCTS, NUTRITION AND ALLERGIES

Meeting dates: 23-25 November 2011
Venue: EFSA, Largo N. Palli 5/a, Parma, 43121

Draft Agenda

| # | Items |
|---|---|
| 1 | Welcome, apologies for absence |
| 2 | Adoption of the agenda of this Plenary meeting & the minutes of the previous Plenary meeting |
| 3 | Declarations of interest |
| 4 | Feedback from EFSA Scientific Committee and other EFSA Panels, and general information from EFSA |
| 5 | Feedback from the Commission on matters relating to the Panel |
| 6 | New requests |
| 7 | General issues on health claims evaluations <ul style="list-style-type: none">7.1 Update on Article 13(5) and 14 applications7.2 Update on Article 13 list claims - Reassessment7.3 Draft guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health (EFSA-Q-2010-01182) – <i>For discussion/possible adoption</i>7.4 Technical report: Outcome of a public consultation on the Draft guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health (EFSA-Q-2011-00306) – <i>For information</i>7.5 Draft guidance on the scientific requirements for health claims related to physical performance (EFSA-Q-2010-01186) – <i>For discussion/possible endorsement for release for public consultation</i> |
| 8 | Applications pursuant to Article 14/13(5) of Regulation (EC) No 1924/2006 - <i>For discussion/possible adoption</i> <ul style="list-style-type: none">8.1 “Coffee C21” and “maintenance of DNA integrity in cells of the body” (Art. 13.5: 0303_DE, EFSA-Q-2011-00783) |

- 8.2 **“Spermidine” and “prolongation of the growing phase (anagen) of hair cycle”** (Art 13.5: 0309_IT, EFSA-Q-2011-00896)
- 8.3 **“sugar beet fibre” and “decreasing intestinal transit time”**(Art 13.5: 0311_DK, EFSA-Q-2011-00971)
- 8.4 **“sugar beet fibre” and “increasing faecal bulk”** (Art 13.5: 0312_DK, EFSA-Q-2011-00972)
- 8.5 **“Diacylglycerol (DAG)” and “reduction of bodyweight”** (Art. 13.5: 0301_UK, EFSA-Q-2011-00751)
- 8.6 **“Barley beta-glucan” and “lowering of blood cholesterol and reduced risk of (coronary) heart disease”** (Art. 14: 0305_BE, EFSA-Q-2011-00798)
- 8.7 **“Barley beta-glucan” and “lowering of blood cholesterol and reduced risk of (coronary) heart disease”** (Art. 14: 0306_SI; EFSA-Q-2011-00799)
- 8.8 **“Bimuno[®] GOS, a mixture of β -galacto-oligosaccharides” and “reduction of intestinal discomfort”** (Art. 13(5): 0299_UK, EFSA-Q-2011-00401)
- 8.9 **“Bimuno[®] GOS, a mixture of β -galacto-oligosaccharides” and “reduction of pathogenic bacteria in the gastrointestinal tract, which is a risk factor for travellers’ diarrhoea”** (Art. 14: 0300_UK, EFSA-Q-2011-00402)
- 8.10 **“Glucosamine sulphate” and “maintenance of joints”** (Art. 13(5): 0309_HU, EFSA-Q-2011-00907)

9 **Novel Foods -*For discussion/ possible adoption***

- 9.1 **Statement on the safety of glucosamine for patients receiving coumarin anticoagulants (EFSA-Q-2011-00770)**

10 **Any other business**